TRE-Ccnd1WT and TRE-Ccnd1K112E mice transgenic for human Ccnd1 with or without the K112E mutation under TRE regulation have been published previously31 (link),32 (link). Pax7rtTA mice contain rtTA-M2 followed by an IRES, mouse Pax7, and polyadenylation tail knocked in to the first exon of the Pax7 locus. Both lines were maintained by breeding heterozygous animals to wild-type animals. Experimental animals (Pax7rtTA/+, Pax7rtTA/+; TRE-Ccnd1WT, and Pax7rtTA/+; TRE-Ccnd1K112E) were generated by intercrossing the two lines and aging the appropriate genotypes until use. All transgenic animals were treated for seven days with doxycycline by providing doxycycline hyclate chow (Envigo, TD.120769), delivering a daily dose of 2-3 mg doxycycline based on consumption of 4-5 grams each day. On the sixth and seventh days, doxycycline hyclate (Thermo Fisher ICN19895510) was injected intraperitoneally at 50 mg/kg in 0.9% NaCl. MuSCs were isolated on the eighth day based on immunophenotype via FACS as described above.